SBRT in unresectable advanced pancreatic cancer: Preliminary results of a mono-institutional experience

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Tozzi, Angelo ^a   Comito, Tiziana ^a   Alongi, Filippo ^a   Navarria, Pierina ^a   Iftode, Cristina ^a   Mancosu, Pietro ^a   Reggiori, Giacomo ^a   Clerici, Elena ^a   Rimassa, Lorenza ^a   Zerbi, Alessandro ^a   Fogliata, Antonella ^b   Cozzi, Luca ^b   Tomatis, Stefano ^a   Scorsetti, Marta ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Pancreas; RapidArc; Stereotactic body radiation therapy

Indexed keywords

ANALGESIC AGENT; GEMCITABINE; ONDANSETRON; DEOXYCYTIDINE;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; NAUSEA; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PRESCRIPTION; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INDUCED EMESIS; RECURRENT CANCER; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; ADENOCARCINOMA; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROCEDURES; RADIOSURGERY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; RADIOSURGERY;

EID: 84879117793     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-148     Document Type: Article

References (24)

1. Jamieson NB, Denley SM, Logue J, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 2011, 18:2318-2328. 10.1245/s10434-011-1560-3, 21267785.
2. Haddock MG, Swaminathan R, Foster NR, et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007, 25:2567-2572. 10.1200/JCO.2006.10.2111, 17577035.
3. Willett CG, Czito BG, Bendell JC, et al. Locally advanced pancreatic cancer. J Clin Oncol 2005, 23:4538-4544. 10.1200/JCO.2005.23.911, 16002845.
4. Small W, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2008, 26:942-947. 10.1200/JCO.2007.13.9014, 18281668.
5. Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002, 53:146-150. 10.1016/S0360-3016(01)02806-1, 12007953.
6. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:801-808. 10.1016/j.ijrobp.2006.12.053, 17379445.
7. Timmerman RD, Kavanagh BD, Cho LC, et al. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007, 25:947-952.8. 10.1200/JCO.2006.09.7469, 17350943.
8. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 58:1017-1021. 10.1016/j.ijrobp.2003.11.004, 15001240.
9. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005, 76:48-53. 10.1016/j.radonc.2004.12.022, 15990186.
10. Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008, 72:678-686. 10.1016/j.ijrobp.2008.01.051, 18395362.
11. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009, 115:665-672. 10.1002/cncr.24059, 19117351.
12. Schellenberg D, Kim J, Christman-Skieller C, et al. Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2011, 81:181-188. 10.1016/j.ijrobp.2010.05.006, 21549517.
13. Polistina F, Costantin G, Casamassima F, et al. Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010, 17:2092-2101. 10.1245/s10434-010-1019-y, 20224860.
14. Didolkar MS, Coleman CW, Brenner MJ, et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 2010, 14:1547-1559. 10.1007/s11605-010-1323-7, 20839073.
15. Mahadevan A, Miksad R, Goldstein M, et al. Induction Gemcitabine And Stereotactic Body Radiotherapy For Locally advanced Nonmetastatic Pancreas Cancer. Int J Radiat Oncol Biol Phys 2011, 81:615-622. 10.1016/j.ijrobp.2010.06.044, 20933343.
16. Rwigema JC, Parikh SD, Heron DE, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2011, 34:63-69. 10.1097/COC.0b013e3181d270b4, 20308870.
17. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
18. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:3778-3785. 10.1200/JCO.2008.20.9007, 2727286, 19581537.
19. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28:3617-3622. 10.1200/JCO.2010.28.1386, 2917317, 20606091.
20. Scorsetti M, Arcangeli S, Tozzi A, et al. Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. Int J Radiation Oncol Biol Phys 2013, 86:336-342.
21. Alongi F, Fogliata A, Clerici E, et al. Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol 2012, 7:204. 10.1186/1748-717X-7-204, 3551769, 23216821.
22. Alongi F, Arcangeli S, Filippi AR, et al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 2012, 17:1100-1107. 10.1634/theoncologist.2012-0092, 22723509.
23. Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol 2012, 51:618-623. 10.3109/0284186X.2011.652738, 22263925.
24. Arcangeli S, Scorsetti M, Alongi F. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol 2012, 84:101-108. 10.1016/j.critrevonc.2011.11.009, 22257653.